Biosimilar sponsors may find the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, intended to ensure their access to reference product for testing, is not as clear as with conventional generics and that more litigation may be needed to address some issues.
Rachel Turow, Teva Pharmaceutical Industries Ltd. associate general counsel and head of US regulatory law and policy, said during...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?